D 69
Pill imprint D 69 has been identified as Didanosine delayed release 200 mg.
Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy.
Didanosine 200 mg is not subject to the Controlled Substances Act.
See also related documents.
Didanosine delayed release Images
- Imprint:
-
D
69 - Strength:
- 200 mg
- Color:
- White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Inactive Ingredients:
- sodium starch glycolate type A potato
carboxymethylcellulose sodium
sodium lauryl sulfate
hypromellose 2910 (3 mPa.s)
magnesium silicate
methacrylic acid - ethyl acrylate copolymer (1:1) type a
diethyl phthalate
silicon dioxide
gelatin
titanium dioxide
ferrosoferric oxide
shellac
- Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Aurobindo Pharma
- National Drug Code (NDC):
- 65862-0311
Advertisement
More Didanosine Delayed Release resources
- Didanosine Chewable/Dispersible Buffered Tablets (Wolters Kluwer)
- Didanosine Delayed-Release Enteric-Coated Capsules (Wolters Kluwer)
- Didanosine Powder Pack (Wolters Kluwer)
- Didanosine Solution (Wolters Kluwer)
- didanosine (Cerner Multum)
- Videx Pediatric (Micromedex) - Includes Dosage Information
- didanosine (Micromedex) - Includes Dosage Information
- Didanosine (AHFS DI)
- Didanosine (FDA)
- Didanosine Oral Solution (FDA)
- Didanosine (Wolters Kluwer)
Search Again
